补肾化瘀解毒方对中晚期非小细胞肺癌化疗患者uPA及PAI-1的影响  

Effects of Bushen Huayu Jiedu Formula on the levels of uPA and PAI-1 in patients with advanced non-small cell lung cancer during chemotherapy

作　　者：钟安朴[1] 许维毅[1] 曹勇[2] 

机构地区：[1]遵义医学院附属医院中医科,遵义563000 [2]暨南大学医学院,广州510632

出　　处：《中华中医药杂志》2016年第1期316-318,共3页China Journal of Traditional Chinese Medicine and Pharmacy

摘　　要：目的:观察补肾化瘀解毒方对中晚期非小细胞肺癌(NSCLC)化疗患者血浆尿激酶型纤溶酶原激活因子(u PA)及其抑制因子-1(PAI-1)的影响及临床疗效。方法:98例符合纳入标准的中晚期NSCLC患者,按随机数字表法分为观察组和对照组各49例,两组患者均给予常规TP方案化疗,对照组加用补肾化瘀解毒方内服,3周为1个疗程,2个疗程后观察血浆u PA及PAI-1的变化情况及临床疗效。结果:观察组治疗后总有效率为63.26%,对照组治疗后总有效率为40.81%,两组比较差异有统计学意义(P<0.05);两组治疗后血浆u PA及PAI-1均下降,观察组下降更明显,两组比较差异有统计学意义(P<0.05)。结论:补肾化瘀解毒方可以通过降低中晚期NSCLC化疗患者血浆u PA及PAI-1,控制肿瘤的生长及转移,值得临床推广应用。Objective：To study the effects of Bushen Huayu Jiedu Formula on the levels of plasma urokinase type plasminogen activator（uPA） and plasminogen activator inhibitor-1（PAI-1）on patient with advanced non-small cell lung cancer（NSCLC） during chemotherapy.Methods：Ninty-eight patients with advanced NSCLC were randomly divided into observation group and control group with 49 cases in each group.All patients were given a regimen of TP,a conventional chemotherapy,while the patients in the observation group were internally given Bushen Huayu Jiedu Formula on the basis of the conventional chemotherapy,3 weeks for one coures of treatment.The clinical curative effect and the levels of plasma uPA and PAI-1 were observed after 2 courses of treatment.Results：After treatment,the total effective rates of the observation group and the control group were 63.26%and 40.81%,respectively.There was statistical significance in the total effective rate between the observation group and the control group（P〈0.05）.The plasma uPA and PAI-1 were decreased in both of the two groups,but they were decreased more in the observation group than that in the control group.Additionally,there was statistical significance in the levels of plasma uPA and PAI-1 between the observation group and the control group（P〈0.05）.Conclusion：Bushen Huayu Jiedu Formula could reduce the level of plasma uPA and PAI-1 in patients with advanced NSCLC during chemotherapy,which would contribute to inhibite the growth and metastasis of tumor.So,it should be promoted in the clinic.

关 键 词：补肾化瘀解毒方 非小细胞肺癌 尿激酶型纤溶酶原激活因子 尿激酶型纤溶酶原激活因子抑制因子1 

分 类 号：R734.2[医药卫生—肿瘤]